Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.

• Status: Completed
• Trial end date: 2022-11-07

Summary

The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose administration under fasting conditions.

• Phase: Phase 1

Details

• Lead Sponsor: Galenicum Health
• Treatments: Metformin; Sitagliptin Phosphate